两任董事长涉同一桩旧案：信邦制药行贿案漩涡下的全产业链之问

Core Viewpoint - Xinfang Pharmaceutical (002390.SZ) has been implicated in a bribery case, with the parent company being sent for prosecution, marking a significant legal challenge for the company and impacting its market value [1][3][18]. Group 1: Legal Issues - The company announced on December 10 that it is under investigation for unit bribery, following a previous case involving its subsidiary [1][3]. - This marks the first time Xinfang Pharmaceutical has appeared in official documents as a "criminal suspect" since its listing in 2010 [3][18]. - The legal ramifications could severely restrict the company's ability to participate in government procurement and public hospital projects for at least three years [30]. Group 2: Financial Performance - In 2024, the company reported a revenue of 60.32 billion yuan, a year-on-year decline of 6.63%, and a net profit of 1.01 billion yuan, down 64.70% [9][24]. - For the first three quarters of 2025, revenue was 42.66 billion yuan, with a net profit of 1.52 billion yuan, reflecting further declines of 6.55% and 13.74% respectively [9][24]. - The company's financial struggles are attributed to its core pharmaceutical distribution business, which saw a revenue drop of 10.03% in 2024 [10][24]. Group 3: Governance and Management - The company has faced governance challenges, with a family-controlled structure leading to concerns about independence and internal controls [27][30]. - High levels of share pledges among the controlling shareholders raise questions about the stability of control amid declining stock prices [27][30]. - The board's effectiveness is questioned due to the close ties of independent directors to the controlling shareholders, leading to a lack of oversight [27][30]. Group 4: Business Model Challenges - The company's reliance on a high sales expenditure model, with sales costs reaching 3.06 billion yuan in 2024, contrasts sharply with its low R&D investment of only 429.26 million yuan in the first three quarters of 2025 [10][11][24]. - The medical services segment, while seen as a growth area, requires significant capital investment to maintain competitiveness, adding pressure to cash flow [11][24].